Mostafa Najafipour

Mostafa Najafipour

Auto-generated profile, based on publicly available information

Mostafa Najafipour

Young Researchers and Elite Club, Ardabil Branch, Islamic Azad University, Ardabil, Iran

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Advanced Pharmaceutical Technology & Research
Verified
Journal Article
Open access
PDF file
FNFarzad Najafipour
Farzad Najafipour
MNMostafa Najafipour
Mostafa Najafipour
MZMasoumeh Zareizadeh
Masoumeh Zareizadeh
Type 2 diabetes is the most common cause of hyperglycemia. It has different prevalence in various populations. It has been found out that type 2 diabetes is a genetic disorder; however, its inheritance and its type have not been well defined. In studying the genes involved in the development of diabetes, several genes have been introduced as candidates; however, the gene or genes involved in diabetes cannot be identified yet. As family diabetes has not been studied in Iran so far, this study was conducted on a population aged over 20 years in east of Tehran. In a population of 14,687 people living in east of Tehran, 180 families with type 2 diabetes were identified. In this research, 802 subjects were female and 792 were male. After oral glucose tolerance test, 40.7% of females and 32.3% of males had diabetes. The incidence of diabetes in females was significantly higher than that in males (P < 0.001). It was found that 656 diabetic patients had age over 20 years, which most of them had age between 41 and 70 years. The highest number of diabetic patients was in the age group of 51–60 years. The percentage of offspring and siblings involvement in this sample was 44% and 53%, respectively. The highest level of involvement among the first-degree family members belonged to sister-brother, followed by father-daughter. This study shows the relationship between family diabetes in Iranian families in a demographic study. By recognizing the family relations, effective measures can be taken to prevent this disease. In the case of type 2 diabetes development in one member of family, the incidence of diabetes in other family members would increase by up to 50%. Thus, screening is suggested for all type 2 diabetic family members continuously so that the disease to be immediately diagnosed and treated to prevent major complications of diabetes.

30 December 2024 in Health Promotion Perspectives
Verified
Journal Article
Open access
PDF file
MNMostafa Najafipour
Mostafa Najafipour
FNFarzad Najafipour
Farzad Najafipour
AOAlireza Ostadrahimi
Alireza Ostadrahimi
MGMaryam Ghavami
Maryam Ghavami
ZRZohreh Razaghi
Zohreh Razaghi
NANaimeh Mesri Alamdari
Naimeh Mesri Alamdari
Background: Sodium-glucose cotransporter-2 (SGLT-2) acts as a key element in the reabsorption of glucose in the kidney. Currently, SGLT-2 inhibitors are FDA-approved for the treatment of type 2 diabetes. It is suggested that the mechanism of action may operate in the treatment of type 1 diabetes mellitus (T1DM), as well. This study aimed to evaluate the application of empagliflozin as an adjunctive to insulin in patients with T1D. Methods: In this double-blind placebo-controlled randomized clinical study, 60 type 1 diabetic patients were randomly assigned to have either once-daily empagliflozin 10 mg or placebo, as an addition to insulin for 12 weeks. The hemoglobin A1C, fasting blood sugar (FBS), 2-hour post-prandial blood sugar, and anthropometric indices were measured before and after 12 weeks intervention. Results: After 12 weeks, empagliflozin resulted in significant reductions of hemoglobin A1C -0.18 (95% CI: -0.37, 0.005, P=0.009), FBS –2.60 mg/dL (95% CI: -6.48, 1.28, P=0.035), 2-hour post-prandial blood sugar -22.56 mg/dL (95% CI: -35.15, 8.97, P<0.0001), and total daily insulin dose –7.6 units (95% CI: -12.4, 2.8, P=0.003). Furthermore, empagliflozin reduced body mass index (BMI) by -0.560 kg (95% CI: -0.640, 1.46, P<0.0001). Empagliflozin was well tolerated in the patients. Also, no case of hypoglycemia, genital and urinary infections, or diabetic ketoacidosis (DKA) was reported. Conclusion: The present study supported the use of empagliflozin alongside insulin as a treatment option for individuals with T1D. Trial Registration: http:// www.irct.ir, identifier: irct20130610013612N12, Registration date: 12/9/2022).

17 July 2020 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
MNMostafa Najafipour
Mostafa Najafipour
MZMasoumeh Zareizadeh
Masoumeh Zareizadeh
FNFarzad Najafipour
Farzad Najafipour
Introduction: The role of stress in the pathogenesis of Graves’ disease has been highlighted in many studies. The hereditary pattern of Graves’ disease is uncertain because various genetic and environmental factors are known. One of the most important environmental factors is stress. Any kind of stress, such as physical and emotional, can flare or create Graves’ disease. Objectives: The aim of this study was to evaluate the clinical and biochemical aspects of "stress-induced" and "non-stress induced" Graves’ disease. Patients and Methods: This study evaluated 148 patients with Graves’s disease. According to perceived stress scale (PSS) all patients were divided into two groups; stress and non-stress induced Graves’ group. Chi-square test was used to determine statistical difference in qualitative variables. Results: The mean ± standard deviation perceived stress scale score in 53 patients in stress induced Graves’ disease was 40.24±6.53 and in 95 patients in non-stress induced Graves’ disease was 18.47±3.90. In this study the onset of Graves’ disease is more severe in the stress induced Graves’ disease, however the level of antithyroid peroxidase was significantly lower. Duration of methimazole since diagnosis and doses of methimazole in the stress induced Graves’ group was shorter than non- stress induced Graves’ group (P<0.001 and 0.032 respectively) and percent of male was significantly higher in stress induced Graves’ group (P=0.002). Conclusion: According to this study, clinical characteristics of stress induced Graves’ disease differ with non-stress induced Graves’ disease. Generally, severity of disease in stress induced Graves’ group was initially more severe (higher FT4 in this group), but duration of disease was shorter than non-stress induced Graves’ disease, and these patients had smaller size of goiter and lower anti-thyroid peroxidase (anti-TPO) antibody (anti-TOP Ab).

4 December 2024 in Journal of Research in Clinical Medicine
Verified
Journal Article
Open access
PDF file
MLMahshid Naser Langroodi
Mahshid Naser Langroodi
AAAkbar Aliasgharzadeh
Akbar Aliasgharzadeh
MNMostafa Najafipour
Mostafa Najafipour
NYNeda Lotfi Yagin
Neda Lotfi Yagin
FNFarzad Najafipour
Farzad Najafipour
Introduction: Acromegaly, characterized by overproduction of growth hormone (GH) and insulin-like growth factor 1 (IGF1), increases the risk of mortality and morbidities. Monitoring is a crucial aspect of managing and treating of acromegaly patients. In various studies, patients with active acromegaly have shown discordance between GH and IGF-1 results after surgery. In this study, the discrepancy between these two tests in monitoring acromegaly patients was evaluated. Methods: The levels of IGF-1 and GH after OGTT in 49 acromegalic patients who underwent surgery at least 3 months earlier and had been referred to clinic for follow-up were analyzed. Clinical and metabolic parameters, GH nadir, and IGF-1 values were compared between groups. Results: Fifty-one percent of patients had normal IGF-1 based on their age and sex, and 57.1% of patients had GHn<1 µg/L. Based on IGF-1 and GHn results, 23 patients had discordant results. The most common pattern of discordance was high IGF-1 and normal GH nadir that was seen in 13 patients. A pattern of high GH and normal IGF-1 was seen in 10 patients. There was a significant difference between the corrected IGF-1 values of the high IGF-1 group and those of active disease group (P=0.001). There was no significant difference in GHn between high GHn group and active disease group (P=0.8). Conclusion: There is a significant inconsistency between the results of IGF-1 and GHn in monitoring of acromegaly patients. Also, when GH-0 is<1 µg/L the use of GHn does not help and there is a need for more frequent monitoring for early diagnosis of the disease recurrence.

1 January 2025 in International Journal of Endocrinology
Verified
Journal Article
Open access
FNFarzad Najafipour
Farzad Najafipour
JJJavad Jafarpour
Javad Jafarpour
ABAmir Bahrami
Amir Bahrami
MMMajid Mobasseri
Majid Mobasseri
MNMitra Niafar
Mitra Niafar
NANaimeh Mesri Alamdari
Naimeh Mesri Alamdari
Background: Acromegaly is a rare but severe condition characterized by the excessive secretion of growth hormone (GH), leading to various metabolic alterations. Treatment options include surgery, pharmacotherapy, and radiotherapy (RT). RT can control the disease biochemically, either alone or in conjunction with medical therapy. This study aimed to evaluate the effectiveness of conventional RT in patients with postoperative acromegaly over a 15‐year follow‐up period, using specific cutoff criteria. Methods: A retrospective analysis was performed on 55 acromegaly patients who were monitored for an average of 15 (13.3–16.7) years and treated with conventional RT (median dose of 52 Gy) following pituitary surgery. Hormonal assessments included baseline and glucose‐suppressed GH and IGF‐1 levels, and side effects associated with RT were evaluated. Results: The baseline GH level decreased from 20.7 (16–25.4) μg/L to 11.2 (8.3–14.1) μg/L ( p < 0.001) at 2 years, further dropping to 5.8 (4.99–6.61) μg/L ( p < 0.001) at 5 years, and to 2.2 (1.66–2.74) μg/L ( p < 0.001) at 10 years after RT. Rates of patients achieving suppressed GH levels < 1 μg/L rose from 9% at 2 years to 25% at 5 years, 42% at 10 years, and 76% at 15 years. IGF‐1 levels normalized in 5% of participants at 2 years, 14% at 5 years, 38% at 10 years, and 60% at 15 years. After 10 years, 78% of patients experienced hypogonadism, 80% experienced hypothyroidism, and 82% experienced hypocortisolism. Neurological complications were reported in 4% of patients 10 years post‐RT, while 4% developed visual impairments and optic neuropathy within 5 years. Conclusion: The results suggest that conventional RT is an effective long‐term management strategy for patients who do not respond adequately to medical therapy or surgery. However, the high incidence of late‐onset hypopituitarism must be taken into account.

20 August 2022 in Health Promotion Perspectives
Verified
Journal Article
Open access
PDF file
AOAlireza Ostadrahimi
Alireza Ostadrahimi
VSVahideh Sadra
Vahideh Sadra
ABAmir Bahrami
Amir Bahrami
ZRZohreh Razzaghi
Zohreh Razzaghi
MNMostafa Najafipour
Mostafa Najafipour
FNFarzad Najafipour
Farzad Najafipour
Background: Clinical evidence of endocrine involvement in coronavirus disease needs further investigation. The aim of the present study was to assess the relationship between hematology and endocrine parameters in coronavirus disease 2019 (COVID-19) infection. Methods: In the present cross-sectional study, a total of 320 patients (215 survivors and 105 non-survivors) with confirmed COVID-19 infection were enrolled. After isolation of serum samples, hematological, biochemical, and hormonal parameters were analyzed. Results: The mean age of survivors and non-survivors was 58.92 (SD: 15.28) and 63.65 (SD: 16.62) years, respectively. The results demonstrated significant differences in free triiodothyronine (FT3) [MD (95% CI): 0.40 (0.10, 0.71), P=0.009], total calcium [MD (95% CI): 0.53 (0.21, 0.86), P=0.003], vitamin D [MD (95% CI): 7.72 (6.38, 9.05), P=0.003], erythrocyte sedimentation rate (ESR) [MD (95% CI): 17.09 (9.38, 22.05), P=0.004) and serum ferritin [Median difference: -1091.9, P<0.001), between survivors and non-survivors, respectively. Conclusion: The results revealed that some hematological and endocrine factors play an important role in prognosis of COVID-19 infection. However, further studies with a larger population are required to clarify the exact effects of COVID-19 on the endocrine system.